Latest News & Features
article
A lot of strides have been made in the field of CRISPR systems, and MilliporeSigma and Arbor Biotechnologies are at the heart of developments. In this unmissable live panel, Millipore’s Senior Corporate Patent Counsel, Ben Sodey, and Kelly Morgan, Head of Legal & IP at Arbor, will share their insights on the latest developments in this arena, and answering a host of questions, including. 20 August 2020
Big Pharma
Sandoz has gathered support for its request for an en banc rehearing of a ruling that blocks it from selling a version of biologic Enbrel until 2029. 20 August 2020
Americas
Johnson & Johnson is set to buy biotech Massachusetts-based Momenta Pharmaceuticals for $6.5 billion, in a move aimed at strengthening its portfolio of autoimmune disease treatments. 20 August 2020
Americas
Mylan launched its generic version of Biogen’s $4 billion-a-year multiple sclerosis drug Tecfidera yesterday, August 19. 20 August 2020
Medtech
Hearing implant manufacturer Cochlear has agreed to pay an additional $75 million to settle a patent infringement case if an original $268 million damages bill is upheld by the US Supreme Court. 19 August 2020
Big Pharma
In a win for Novartis Pharmaceuticals, the US District Court for the district of Delaware has upheld the patent on its top-selling multiple sclerosis drug Gilenya. 18 August 2020
Medtech
An Amazon seller has agreed to pay almost $200,000 to settle a trademark lawsuit brought by face mask manufacturer 3M over alleged price gouging. 17 August 2020
Big Pharma
The European Commission reached its first agreement to supply EU member states with an experimental COVID-19 vaccine with AstraZeneca late last week. 17 August 2020
Americas
The US Court of Appeals for the Federal Circuit has thrown out a patent infringement lawsuit brought by two Illinois doctors against more than 300 hospitals. 17 August 2020
Big Pharma
Big Pharma is looking for solutions to the COVID-19 pandemic wherever it can find them, so drug repurposing is more important than ever, as research lawyers Jakob Wested and John Liddicoat argue. 14 August 2020